Prof. Dr. Kevin M. Brindle
![](https://mlpq7ncp5jqb.i.optimole.com/w:587/h:829/q:mauto/ig:avif/http://smartdrugs2024.com/wp-content/uploads/2024/03/kevin_crop.png)
Kevin M. Brindle, D. Phil., is Emeritus Professor of Biomedical Magnetic Resonance in the Department of Biochemistry at the University of Cambridge and a Senior Group Leader in the Cancer Research UK Cambridge Institute. He got his BA (Biochemistry,1978) and D. Phil (1982) in Oxford, before becoming a Royal Society University Research Fellow in 1986. He moved to a lectureship in Manchester in 1990 and in 1993 to a lectureship in Cambridge, where he became Professor in 2005. The current focus of his work is to develop novel imaging methods to detect cancer, disease progression and to monitor early tumour responses to treatment. He was elected a Fellow of the Academy of Medical Sciences in 2012, a Fellow of the European Academy of Cancer Sciences in 2014, a Fellow of the International Society of Magnetic Resonance in 2020 and a Fellow of the Royal Society in 2020. He was President of the European Society for Molecular Imaging in 2018 and was awarded the European Society of Molecular Imaging Award in 2013 and the Gold Medal of the World Molecular Imaging Society in 2014.
Matt Morrison PhD
Matt Morrison is the Head of Operations and Supply Chain at Blue Earth Diagnostics Ltd. He joined Blue Earth Diagnostics in 2021. Matt has more than 25 years of experience in the nuclear medicine industry. Prior to joining Blue Earth Diagnostics, he held leadership positions of increasing responsibility in R&D and Commercial product management at GE HealthCare. Matt holds a B.Sc. in Toxicology and Pharmacology and a Ph.D. from University College London.
Proudly powered by WordPress